Editas Medicine at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Editas Medicine brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on targeted lipid nanoparticles that edit or engineer cells inside the body. One project makes CAR T cells in the body and achieves meaningful B cell depletion, and another sets up a GMP-ready manufacturing platform for those particles.

OrganizationESGCT 2026 Attendance
Editas Medicine
Cambridge, Massachusetts
editasmedicine.com
Biotech
CRISPR gene editing company developing in vivo editing medicines delivered by targeted lipid nanoparticles, including in vivo CAR-T and cholesterol-lowering programs.
Poster
Wed Oct 28
1:30pm–3:30pm
Development of a configurable, GMP‑ready manufacturing platform for targeted LNP therapeutics
Manufacturing
Poster
Wed Oct 28
1:30pm–3:30pm
Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion
Immunotherapy and CAR T cells

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Editas Medicine

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction